RELiZORB mimics the function of pancreatic lipase and delivers absorbable fats to your patients with fat malabsorption who require enteral feeding.


The use of RELiZORB is supported by the Consensus Statement, recently published in the Journal of Cystic Fibrosis.

Please consult the following referenced publications for more information on fatty acids and fat malabsorption.

Consensus Statement: Journal of Cystic Fibrosis

Synopsis: The consensus statement characterizes RELiZORB as a “physiologically superior product,” with “proven success in a real-world setting,” which “can produce measurable, clinically relevant benefits.” The statement further observed that, “despite its effectiveness and intuitive sense, RELiZORB is frequently unavailable to patients due to the vicissitudes of insurance approvals in the US.” This lack of access prompted the authors to develop an independently prepared consensus statement to highlight these patient challenges.

For more information on how to order RELiZORB, contact RELiZORB Support Services at 1-844-632-9271.


This information is intended for
US healthcare professionals


You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.